Announcement • Jul 17
Perspective Therapeutics Data On 212Pb VMT-a-NET Accepted For Oral Presentation At ESMO Congress 2026 Perspective Therapeutics, Inc. announced that updated data on the Company’s [212Pb]VMT-a-NET program have been accepted for presentation at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. Presenter: Thorvardur Halfdanarson, Mayo Clinic Comprehensive Cancer Center. Abstract Title: Cohort level safety and efficacy results for [212Pb]VMT-a-NET in advanced somatostatin receptor subtype 2 (SSTR2+)-expressing neuroendocrine tumors (NETs): Cohorts 1–3. Abstract Number: 2396RO. Session Type: Rapid Oral presentation. Session Title: Rapid oral: NETs and endocrine tumours. Session Date: October 23, 2026. Session Time: 4:15 – 5:45pm CEST /10:15 – 11:45am EDT. Presentation Time: 4:25 – 4:30pm CEST /10:25 – 10:30am EDT. Perspective designed [212Pb]VMT-a-NET to target somatostatin receptor subtype 2 (SSTR2), and to deliver the alpha-emitting radioisotope lead-212, or ²¹²Pb, to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-a-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies (RPT). Interim clinical data from the study, with a data cut-off date of April 17, 2026, were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2026. These data included efficacy results for half of the patients in Cohort 2 and both patients in Cohort 1. Initial efficacy data for the remaining patients in Cohort 2 and patients in Cohorts 3 and 4 are pending. The Company plans to submit additional data for presentation at future medical conferences in 2026 and 2027. The Company is advancing a portfolio of clinical-stage programs in the U.S., including VMT-a-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors). The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary 224Ra/212Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations. Announcement • Jul 08
Perspective Therapeutics, Inc. Announces Executive Changes Perspective Therapeutics, Inc. announced the appointment of Paul Lyne, Ph.D., as Chief Science Officer. Dr. Lyne joined Perspective with more than 25 years of pharmaceutical and biotechnology industry experience spanning target discovery, drug discovery, early clinical development, portfolio strategy, and organizational leadership. Most recently, he served as Senior Vice President and Head of Oncology Research at Merck KGaA, where he led a global research organization spanning cancer cell signaling, immuno-oncology, and antibody-drug conjugates. Throughout his career, Dr. Lyne has helped advance more than 30 oncology programs into clinical development and contributed to multiple approved cancer medicines. He has also led external innovation initiatives and built high-performing scientific organizations focused on translating breakthrough science into transformative therapies for patients. Perspective Therapeutics, Inc. also announced that Michael K. Schultz, Ph.D., co-founder and the Company’s long-time Chief Science Officer, transitioned to the role of Senior Scientific Advisor & Co-Founder as part of a planned transition toward retirement. Dr. Schultz helped lay the scientific groundwork that ultimately led to the creation of the Company, and his leadership, scientific vision, and passion for discovery have touched nearly every aspect of the Company's progress. Dr. Schultz will continue in his advisory role as Senior Scientific Advisor & Co-Founder. Announcement • Jun 04
Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study Perspective Therapeutics, Inc. announced that the first meningioma patient was dosed with [212Pb]VMT-a-NET in the Company’s ongoing Phase 1/2a study. The new cohort is intended to evaluate the safety, dosimetry, and preliminary anti-tumor activity of lead-based alpha-particle therapy with [212Pb]VMT-a-NET for meningioma (LEMONaDE). The initiation of the meningioma cohort reflects the Company’s broader strategy to evaluate [212Pb]VMT-a-NET across somatostatin receptor subtype 2 (SSTR2)-expressing tumor types beyond neuroendocrine tumors (NETs). Meningiomas are the most common primary brain tumors in adults, accounting for ~40% of all central nervous system tumors diagnosed annually in the United States. Approximately 20% of all diagnosed meningioma cases are grades 2 and 3 by World Health Organization (WHO) 2021 grading, while approximately 30% of patients with diagnosed grade 1 disease either have inoperable disease or experience recurrence of their disease. Although surgery and radiation remain standard treatments, patients with recurrent, progressive, or unresectable disease often face limited therapeutic options and poor long-term outcomes. Meningiomas consistently express SSTR2, making them an attractive target for targeted radiopharmaceutical therapy. Perspective designed [212Pb]VMT-a-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-a-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies (RPT). Interim analysis with a data cut-off date of April 17, 2026 was recently reported at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2026, including efficacy data on half of the patients in Cohort 2 and both patients in Cohort 1. Initial efficacy data for the remaining patients in Cohort 2 and eight patients in Cohort 3 are pending, and submissions for presentations at additional medical conferences during 2026 are planned. 
